ATE387460T1 - Verfahren und kit zur beurteilung des ausbruchs von rheumatoider arthritis - Google Patents

Verfahren und kit zur beurteilung des ausbruchs von rheumatoider arthritis

Info

Publication number
ATE387460T1
ATE387460T1 AT03700501T AT03700501T ATE387460T1 AT E387460 T1 ATE387460 T1 AT E387460T1 AT 03700501 T AT03700501 T AT 03700501T AT 03700501 T AT03700501 T AT 03700501T AT E387460 T1 ATE387460 T1 AT E387460T1
Authority
AT
Austria
Prior art keywords
rheumatoid arthritis
protein
kit
outbreak
assessing
Prior art date
Application number
AT03700501T
Other languages
English (en)
Inventor
Shunichi Shiozawa
Koichiro Komai
Mikiko Nakatsukasa
Original Assignee
Shunichi Shiozawa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shunichi Shiozawa filed Critical Shunichi Shiozawa
Application granted granted Critical
Publication of ATE387460T1 publication Critical patent/ATE387460T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Rehabilitation Therapy (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
AT03700501T 2002-01-11 2003-01-08 Verfahren und kit zur beurteilung des ausbruchs von rheumatoider arthritis ATE387460T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002005326A JP4242590B2 (ja) 2002-01-11 2002-01-11 慢性関節リウマチの疾患感受性遺伝子、及びその利用

Publications (1)

Publication Number Publication Date
ATE387460T1 true ATE387460T1 (de) 2008-03-15

Family

ID=19191091

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03700501T ATE387460T1 (de) 2002-01-11 2003-01-08 Verfahren und kit zur beurteilung des ausbruchs von rheumatoider arthritis

Country Status (11)

Country Link
US (1) US7615341B2 (de)
EP (1) EP1471143B1 (de)
JP (1) JP4242590B2 (de)
KR (1) KR100976005B1 (de)
AT (1) ATE387460T1 (de)
CA (1) CA2473218C (de)
DE (1) DE60319342T2 (de)
DK (1) DK1471143T3 (de)
ES (1) ES2301778T3 (de)
PT (1) PT1471143E (de)
WO (1) WO2003060126A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4657757B2 (ja) * 2005-02-23 2011-03-23 株式会社膠原病研究所 肺高血圧症発症関連遺伝子を用いた肺高血圧症の診断および治療
JP2006325528A (ja) * 2005-05-27 2006-12-07 Institute For Rheumatic Diseases Co Ltd 糖尿病性網膜症の診断および予防
JP4657857B2 (ja) * 2005-08-25 2011-03-23 株式会社膠原病研究所 メタボリックシンドロームの診断および予防
JP2009136229A (ja) * 2007-12-07 2009-06-25 Institute For Rheumatic Diseases Co Ltd 自己免疫疾患モデル細胞又は自己免疫疾患モデル動物の作製方法、並びに自己免疫疾患の診断方法
JP2018518203A (ja) * 2015-06-24 2018-07-12 オックスフォード バイオダイナミックス リミテッド エピジェネティックな染色体相互作用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585464A (en) 1993-02-19 1996-12-17 Theratech, Inc. Recombinant antigen for diagnosing rheumatoid arthritis
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
EP0821728B1 (de) 1995-04-06 2004-08-11 Regeneron Pharmaceuticals, Inc. Tie-2 liganden, herstellungsverfahren und verwendung
CA2289961C (en) 1997-05-15 2009-03-31 Shunichi Shiozawa A gene causative of rheumatoid arthritis, method for diagnosing rheumatoid arthritis, and method for identifying causative factors of rheumatoid arthritis
WO2000002587A1 (en) 1998-07-13 2000-01-20 Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
AU5472899A (en) * 1998-08-20 2000-03-14 Incyte Pharmaceuticals, Inc. Human angiopoietin-3
EP1164190B1 (de) * 1999-03-20 2011-06-29 Shunichi Shiozawa Rheumatische Arthritis-Gen und Verfahren für die Diagnose von rheumatischer Arthritis
CA2372053C (en) * 1999-04-28 2008-09-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
DE10100586C1 (de) 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
JP3596433B2 (ja) * 2000-06-29 2004-12-02 株式会社デンソー 車載用電子制御装置
WO2002034912A1 (fr) 2000-10-24 2002-05-02 New Ind Res Organization Genomes participant a l'arthrite rhumatoide, procede de diagnostic de celle-ci, procede d'evaluation de la possibilite d'apparition de celle-ci, kit de diagnostic et methode et remedes therapeutiques destines a l'ar

Also Published As

Publication number Publication date
EP1471143A4 (de) 2005-09-14
AU2003201847A1 (en) 2003-07-30
JP4242590B2 (ja) 2009-03-25
US7615341B2 (en) 2009-11-10
PT1471143E (pt) 2008-05-20
JP2003204790A (ja) 2003-07-22
DE60319342T2 (de) 2009-03-19
CA2473218C (en) 2011-07-19
EP1471143A1 (de) 2004-10-27
DE60319342D1 (de) 2008-04-10
US20050176004A1 (en) 2005-08-11
DK1471143T3 (da) 2008-06-16
KR20040077715A (ko) 2004-09-06
KR100976005B1 (ko) 2010-08-17
EP1471143B1 (de) 2008-02-27
CA2473218A1 (en) 2003-07-24
WO2003060126A1 (fr) 2003-07-24
ES2301778T3 (es) 2008-07-01

Similar Documents

Publication Publication Date Title
CY1118403T1 (el) Αναλυση βιοχημικης ικανοτητας και μεθοδοι για τη μειωση της ανθεκτικοτητας του hiv στη θεραπεια
ATE353974T1 (de) Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
WO2002082075A3 (de) Verfahren zum nachweis chronisch-demenzieller erkrankungen, zugehörige peptide und nachweisreagenzien
DE69434926D1 (de) Menschlicher gewebsinhibitor von metalloproteinase-4
IL154794A0 (en) Remedies for heart failure
ATE438737T1 (de) Verfahren für den nachweis von erkrankungen
DE60041355D1 (de) Verfahren zur detektion von erkrankungen
WO2002059604A3 (en) Diagnosis and treatment of multiple sclerosis
ATE415175T1 (de) Ace2-aktivierung zur behandlung von herz, lungen, und nierenkrankheit und bluthochdruck
DK0750672T3 (da) DNA-sekvenser for matrix-metalproteaser, deres tilvejebringelse og anvendelse
CY1105380T1 (el) Προτιμωμενα τμηματα της νευρικης νηματικης πρωτεϊνης και μεθοδοι χρησης αυτων
DE68928728D1 (de) Diagnose von retinoblastoma
ATE387460T1 (de) Verfahren und kit zur beurteilung des ausbruchs von rheumatoider arthritis
WO2008016385A3 (en) Deacylase polypeptides, deacylase polynucleotides, and methods of use thereof
DK0876491T3 (da) Langt QT-syndrom-gen, der koder for KVLQT1 og dets association med minK
ATE435657T1 (de) Therapeutische zubereitung von hochreinem fviia und verfahren zu dessen gewinnung
DE69204157T2 (de) Verfahren zur bestimmung von anti-rns-antikörpern.
ATE534902T1 (de) Replikationsproteinn ciz1
ATE329638T1 (de) Vorrichtung, um in einem zielgebiet eines menschlichen oder tierischen körpers einen künstlichen isolierten kreislauf zu etablieren
WO2008037720A3 (en) Means and methods for diagnosing and/or treating a subject at risk of developing heart failure
DE69734890D1 (de) Rdgb-proteine
EE200000478A (et) Peptiid, seda kodeeriv geen, diagnostiline reagent ja diagnostiline reaktiivikomplekt ning vaktsiinkasutamiseks riketsioosi ravis
ATE407944T1 (de) Mit trp-proteinen verwandtes protein mtr1 und dieses codierende dna-sequenz
AU2003299389A8 (en) PRP detection method using an aminoglycoside antibiotic

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1471143

Country of ref document: EP